126 related articles for article (PubMed ID: 12743986)
21. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
22. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
Meo S; Dittadi R; Peloso L; Gion M
Int J Biol Markers; 2004; 19(4):282-8. PubMed ID: 15646834
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
27. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
28. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
29. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
30. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Linderholm BK; Gruvberger-Saal S; Fernö M; Bendahl PO; Malmström P
Breast; 2008 Oct; 17(5):484-91. PubMed ID: 18508268
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
34. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
[TBL] [Abstract][Full Text] [Related]
36. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.
Saadoun H; Lamy PJ; Thezenas S; Pouderoux S; Bibeau F; Montels F; Romieu G; Colombo PE; Gutowski M; Jacot W
Future Oncol; 2014 Feb; 10(2):195-209. PubMed ID: 24490606
[TBL] [Abstract][Full Text] [Related]
38. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
39. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
[TBL] [Abstract][Full Text] [Related]
40. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Bouchet C; Ferrero-Poüs M; Hacène K; Becette V; Spyratos F
Int J Biol Markers; 2003; 18(3):207-17. PubMed ID: 14535592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
